Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma

NCT02619682 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Plasma Cell Myeloma
Transplant-Related Carcinoma

Interventions

DRUG: Ixazomib Citrate
OTHER: Laboratory Biomarker Analysis
DRUG: Lenalidomide

Sponsor

Fred Hutchinson Cancer Center